he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源位址
- 2022-05-04一问一答聊聊“生酮蔬果”
- 2022-05-02隐源性癫痫发生率翻倍
- 2022-04-28甲状腺功能减退鉴别诊断分析方法有哪些
- 2022-04-252013年国际抗癫痫联合会抗癫痫小儿使用指南
- 2022-04-21隐源性癫痫死亡率差不多
- 2022-04-13抗癫痫药物预防新发癫痫:任重而道远
- 漳州市中医院灵活引才活力
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 「你我参与了感染病的诊断和治疗」京港感染论坛2015
- 全国原发性肺癌标准化诊疗师培训会议
- 恶性事件!贵州74岁医生一家三口!【非医患事件】
- 癫痫的治疗费用是多少?
- 总是担心月经不调?满足以下要求,不用太担心。
- 哪些疾病会引起血精症?
- 月经性癫痫患者妊娠期癫痫控制更好
- Environmental Health Perspectives:空气污染导致脑炎,减少精子数量
- 上海率先探索异地就医门诊费直接结算
- 常见的癫痫病因有哪些?
- 胰高血糖素瘤 胰高血糖素瘤的临床表现是什么?
- 癫痫患者手术评估新型工具
- 癫痫治疗障碍仍难以克服
- CSP2016:李凌江教授谈论了与应激创伤障碍相关的问题
- 你的大姨妈通常停留几天?超过这个数字,大部分子宫疤痕累累
- 膀胱镜主要能发现什么,有危险吗?
- 【预约直播】铿锵的论道 不炎,越来越多--「郁金香论坛」学术沙龙即将举行
- 2015 神经系统疾病诊疗进展
- 泡温泉时不能忽视的事情
- NEJM:“星星的孩子”儿童期和青少年期鼻内催产素有效?
- 久坐,不喜欢喝水会引起尿道炎吗?如何预防尿道炎?
- 什么是治疗癫痫 癫痫有这些偏方?
- 口服避孕药能治疗痛经,不会导致肥胖或难以怀孕吗?
- 梅干腹 脑裂畸形1例
- 年轻人当兵体检标准
- 《西方慢性疾病防治基层医生诊疗手册:神经病学分册》定稿出版
- 水果虽难看可能愈来愈健康
- 治疗癫痫病的最佳方式如何能治好
- 癫痫不可惧怕,“你惧怕它”才可惧怕!
- 欧盟扩展批准后优时比抗癫痫药物 Vimpat 用于儿童患者
- 前瞻性研究表明癫痫与卒中之间发挥作用联系
- nus癫痫用药Trokendi XR已获FDA上市批准
- 新型“辅助工具”用于癫痫患者手术评估
- 药企实验室(研发/QC)规范管理与 ICH指南及原产地最新进展
- 油煎刀鱼 香酥的香甜食品
- 治台好癫痫病比较好的方法是什么
- 怎样摄入抗癫痫药物可以降低副反应
- Circ ep:心电图机自动诊断可能漏诊以外QTc延长者